Risk Adapted Spinal Cord/Cauda Constraint Relaxation for High-risk Patients With Metastatic Epidural Spinal Cord Compression Undergoing Spine Stereotactic Radiosurgery

M.D. Anderson Cancer Center logo

M.D. Anderson Cancer Center

Status and phase

Begins enrollment this month
Phase 2

Conditions

Metastatic Epidural
Spine Stereotactic
Spinal Cord

Treatments

Radiation: Stereotactic Radiosurgery

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT06204315
NCI-2024-00049 (Other Identifier)
2023-0287

Details and patient eligibility

About

To learn about the safety of a procedure called cord dose escalated spine stereotactic radiosurgery (CDE-SSRS) in patients with MESCC.

Full description

Primary Objectives The primary protocol objectives are to establish the safety of CDE-SSRS alone in participants with MESCC. Specifically, we aim to maintain an RM risk no greater than 1%. RM will be defined as non-functional paresis per the McCormick score (i.e., Grade D). Secondary Objectives Secondary objectives include pain control as measured by the Brief Pain Inventory, quality of life as measured by the EQ-5D, symptom burden as measured by the MDASI-SP, overall survival, toxicity, ambulatory rate and cost-effectiveness. LC will be defined radiographically with serial MRI scans by the study radiologist per SPINO criteria.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Greater than or equal to 18 years old
  2. Radiographically documented spinal metastasis on spine MRI within 4 weeks of registration
  3. Proximity of spinal metastasis to spinal cord or cauda equina which precludes achieving a GTV Dmin of at least 14 Gy per the PI
  4. All participants must be able to receive single fraction SSRS at the site of interest with 0.01 cc of the spinal cord receiving 14-16 Gy and/or 0.01 cc of the cauda equina receiving 18-20 Gy. The goal of treatment is to select the minimal dose to the organ at risk which will achieve a GTV Dmin of 14 Gy at the treating physician's discretion.
  5. Maximum of 3 contiguous vertebral levels involved with metastasis in the spine to be irradiated in a single session
  6. All participants must be able to receive a single fraction spine radiosurgery at the designated site of interest to at least a dose of 18 Gy
  7. All participants must have a vertebral level site of interest from C1 to S2
  8. Signed informed consent
  9. Diagnosis of cancer excluding ultra-radiosensitive histologies (see 4.2)
  10. Motor strength ≥ 4 out of 5 in extremity or extremities affected by the level of cord compression
  11. ECOG ≤ 2

Exclusion criteria

  1. Participants with ultra-radiosensitive histologies (lymphoma, multiple myeloma/plasmacytoma)
  2. Prior history of radiation at the spinal site of interest
  3. Inability to lie supine comfortably for ≥ 60 minutes
  4. Progressive neurological deficits due to compression
  5. Inability of obtain an MRI
  6. Inability or refusal to undergo an MR simulation
  7. No eligible for single fraction SSRS for any reason
  8. Participants who are pregnant

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

60 participants in 1 patient group

Stereotactic Radiosurgery
Experimental group
Description:
A non-invasive, non-surgical procedure that precisely delivers radiation to cancer on the spine while avoiding surrounding, healthy tissue.
Treatment:
Radiation: Stereotactic Radiosurgery

Trial contacts and locations

1

Loading...

Central trial contact

Amol Ghia, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems